THEY SUPPORT US
At Brenus Pharma, we develop a new generation of treatments that will overcome limitations of classical immunotherapies and cell therapies— poor efficacy on cold tumors, manufacturing cost and supply issues— and improve the patient’s access to innovation
Proprietary SGC off-the-shelf platform recapituling both the space and time heterogeneity of the tumor to generate first-in-class treatments
A team of expert leaders and developpers of immuno oncology therapies backed by €30 million euro in funding
A standardized and patented platform offering a limitless potential to address significant unmet needs by reducing cost and symplifying supplies
leading to
Example of colorectal cancer (CRC): a cold tumor defined by heterogeneity, plasticity and treatment resistances
95% of patients (MSS type) have no other solution than outdated chemotherapies
5-year survival < 12% 2nd leading cause of cancer mortality worldwide
No immune reaction can be initiated toward tumor cells
Inefficiency of classical immunotherapy
From “off-the-shelf” tumor banks to first-in-class immunotherapies
Enriched with the molecular fingerprints of tumor heterogeneity and resistances.
Designed to safely unlock the immune system to fight back
+
DNFB HAPTEN
DINITROFLUOROBENZENE
CANCER RELATED PROTEINS
> Using standards of care and physical shock
> Precision medicine applied to large patient populations
> Proteogenomic profiling matched with biopsies datasets
> Data science & deep learning prediction tools
> Fonctionnal validation by immunoassays
> GMP ready & specifically replicable to other solid tumors
> Platform & Product worldwide patented
CRC, PDAC, HCC
OVARIAN CANCER
FUTURE DEVELOPMENT
other indications
colorectal cancer
other indications
2nd cause of cancer mortality
colorectal cancer
6th cause of cancer mortality
3rd cause of cancer mortality
Invested since 2020
Clinical candidates advancing toward IND filing by 2027
Clinical sites open in 2025 Phase I/II for colorectal cancer patients in 1L (EU & US expansion planned)
patients treatable per batch thanks to our standardized & scalable platform
Eligible patients by 2029
J.Gardette
Co-founder, president
B. Pinteur
Co-founder & CSO
P. Bravetti
CEO
C. Tortorelli
Sr Lead medical affairs
L. Chalus
Head of CMC Operations
D. Ezzedine
Board Member
PMC, Utrecht (NE)
Former Gustave Roussy director
CGFL,
Dijon
University of Pittsburgh,
Pennsylvania
Johns Hopkins University,
Baltimore, Maryland
Academic Hospital
& CIMA of Navarra
Institut Bergonié, Bordeaux Gustave Roussy, Paris
Chirec Cancer Institute,
Brussels
Hospital Georges Pompidou,
Paris
2024 AWARD BEST BIOTECH (FR)
2024 HEALTHCARE AWARD (FR)
2024 MOST PROMISING PROJECT AWARD (EU)
ALUMNI 2023 CANCER STREAM (CAN)
AWARD 2022 (USA)
ALUMNI 2022 (USA)
2022 NOMINATION BEST PHARMA STARTUP (USA)
2024 AWARD
BEST BIOTECH (FR)
2024 AWARD BEST BIOTECH (FR)
2024 HEALTHCARE AWARD (FR)
2024 MOST PROMISING PROJECT AWARD (EU)
ALUMNI 2023 CANCER STREAM (CAN)
AWARD 2022 (USA)
ALUMNI 2022 (USA)
2022 NOMINATION BEST PHARMA STARTUP (USA)
2021 MATWIN
BORD AWARD (FR)
Copyright 2022 Brenus Pharma – All rights reserved
Parc Industriel Tech Lavaur La Bechade, 63500 Issoire, France – contact@brenus-pharma.com
Head of the Scientific Board of Brenus Pharma
Director of the Translational Research Center for Molecular Medicine at the Georges-François Leclerc Center, Dijon, France
Dr. Ghiringhelli is a leading expert in molecular medicine and translational research. He was recently named a laureate for the second time by the Amgen France Fund for Science and Humanity, recognizing his exceptional contributions to the field.
Distinguished Professor, Department of Immunology, University of Pittsburgh School of Medicine
Dr. Finn is a pioneer in cancer immunology, known for her groundbreaking work on tumor antigens and preventive cancer vaccines. A former President of the American Association of Immunologists, she has received prestigious honors such as the AAI Lifetime Achievement Award, the AACR Lloyd Old Cancer Immunology Prize, and the SITC Richard V. Smalley Memorial Award.
Assistant Professor of Oncology, Johns Hopkins Hospital
Dr. Yarchoan is a liver cancer specialist at Johns Hopkins, where he leads research on cancer immunotherapies and co-directs the Liver Cancer Clinic. He has received honors such as the ASCO Young Investigator Award and the Cholangiocarcinoma Foundation’s Mark R. Clements Award.
Co-Director, Department of Immunology and Immunotherapy, CIMA, University of Navarra
Renowned immunologist with international experience in translational research, Dr. Melero leads the Immunotherapy Department at CIMA and has held roles at Bristol Myers Squibb in the U.S. He is a key expert in cancer immunotherapy and immune mechanisms.
Head of Early Phase Trials Unit, Institut Bergonié
Head of Precision Medicine, Gustave Roussy
Internationally recognized for his work on sarcomas and rare cancers, Pr. Italiano leads early-phase research and precision medicine initiatives. Author of 160+ publications, he is among the most cited oncology researchers.
Head of Oncology Department & Director, Chirec Cancer Institute
Internationally recognized for his expertise in breast cancer, Pr. Awada leads the Chirec Cancer Institute and has over 35 years of experience in oncology. He plays a key role in major societies like ASCO, ESMO, and EORTC, driving innovation in cancer treatment and research
Professor at Université de Paris, Head of Gastroenterology and GI Oncology at Georges Pompidou Hospital
Prof. Taieb is a renowned expert in gastrointestinal oncology, particularly in colorectal and pancreatic cancers. He has led over 10 national and international Phase II/III trials and authored more than 400 scientific publications. Active in ESMO and ASCO, he also sits on the editorial board of ESMO GI Oncology, driving innovation through clinical and translational research.
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
